Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: A meta-analysis of randomized controlled trials

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 446-453

  Xu, Huajun ^a   Yi, Hongliang ^a   Guan, Jian ^a   Yin, Shankai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Continuous positive airway pressure (CPAP); Lipids; Meta analysis; Obstructive sleep apnea syndrome (OSAS)

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ANTHROPOMETRY; CHOLESTEROL BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; META ANALYSIS; METABOLIC SYNDROME X; OBESITY; OXYGEN DESATURATION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDERED BREATHING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; DYSLIPIDEMIAS; RISK FACTOR; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CONTINUOUS POSITIVE AIRWAY PRESSURE; DYSLIPIDEMIAS; HUMANS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84900872409     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.034     Document Type: Review

References (46)

1. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disord ered breathing among middle-aged adults. NEngl J Med 1993, 328(17):1230-1235.
2. Patil S.P., Schneider H., Schwartz A.R., et al. Adult obstructive sleep apnea: pathophysiology and diagnosis. Chest 2007, 132(1):325-337.
3. Kono M., Tatsumi K., Saibara T., et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007, 131(5):1387-1392.
4. Börgel J., Sanner B.M., Bittlinsky A., et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006, 27(1):121-127.
5. Can M., Açikgöz S., Mungan G., et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006, 129(2):233-237.
6. Berg S. Obstructive sleep apnoea syndrome: current status. Clin Respir J 2008, 2(4):197-201.
7. Strollo P.J., Rogers R.M. Obstructive sleep apnea. NEngl J Med 1996, 334(2):99-104.
8. Gordon P., Sanders M.H. Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome. Thorax 2005, 60(1):68-75.
9. Surani S., Subramanian S. Effect of continuous positive airway pressure therapy on glucose control. World J Diabetes 2012, 3(4):65-70.
10. Coughlin S.R., Mawdsley L., Mugarza J.A., et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007, 29(4):720-727.
11. Comondore V.R., Cheema R., Fox J., et al. The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial. Lung 2009, 187(1):17-22.
12. Craig S.E., Kohler M., Nicoll D., et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Thorax 2012, 67(12):1090-1096.
13. Kohler M., Stoewhas A.C., Ayers L., et al. Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2011, 184(10):1192-1199.
14. Sharma S.K., Agrawal S., Damodaran D., et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. NEngl J Med 2011, 365(24):2277-2286.
15. Robinson G.V., Pepperell J.C., Segal H.C., et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004, 59(9):777-782.
16. Michailidis V., Steiropoulos P., Nena E., et al. Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea. Open Cardiovasc Med J 2011, 5:231-238.
17. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269.
18. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
19. Phillips C.L., Yee B.J., Marshall N.S., et al. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomized, placebo-controlled crossover trial. Am J Respir Crit Care Med 2011, 184(3):355-361.
20. Myhill P.C., Davis W.A., Peters K.E., et al. Effect of continuous positive airway pressure therapy on cardiovascular risk factors in patients with type 2 diabetes and obstructive sleep apnea. JClin Endocrinol Metab 2012, 97(11):4212-4218.
21. Lam J.C., Lam B., Yao T.J., et al. Arandomized controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J 2010, 35(1):138-145.
22. Toyama Y., Chin K., Chihara Y., et al. Association between sleep apnea, sleep duration, and serum lipid profile in an urban, male, working population in Japan. Chest 2013, 143(3):720-728.
23. Trzepizur W., Le Vaillant M., Meslier N., et al. Independent association between nocturnal intermittent hypoxemia and metabolic dyslipidemia. Chest 2013, 143(6):1584-1589.
24. Ip M.S., Lam K.S., Ho C., et al. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000, 118(3):580-586.
25. Kiely J.L., McNicholas W.T. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000, 16(1):128-133.
26. Sharma S.K., Kumpawat S., Goel A., et al. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007, 8(1):12-17.
27. McArdle N., Hillman D., Beilin L., et al. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007, 175(2):190-195.
28. Dorkova Z., Petrasova D., Molcanyiova A., et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008, 134(4):686-692.
29. Barceló A., Barbé F., de la Peña M., et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 2008, 63(11):946-950.
30. Cuhadaroglu C., Utkusavas A., Ozturk L., et al. Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. Lung 2009, 187(2):75-81.
31. Davies R.J., Turner R., Crosby J., et al. Plasma insulin and lipid levels in untreated obstructive sleep apnoea and snoring; their comparison with matched controls and response to treatment. JSleep Res 1994, 3(3):180-185.
32. Barceló A., Barbé F., Llompart E., et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004, 117(2):118-121.
33. Li C., Zhang X.L., Liu H., et al. Association among plasma interleukin-18 levels, carotid intima-media thickness and severity of obstructive sleep apnea. Chin Med J Engl 2009, 122(1):24-29.
34. Mirrakhimov A.E., Polotsky V.Y. Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target?. Front Neurol 2012, 3:149.
35. Imadojemu V.A., Mawji Z., Kunselman A., et al. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest 2007, 131(5):1406-1413.
36. M1 Miller, Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123(20):2292-2333.
37. Lévy P., Pépin J.L., Arnaud C., et al. Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. Eur Respir J 2008, 32(4):1082-1095.
38. Fava C., Dorigoni S., Dalle Vedove F., et al. Effect of continuous positive airway pressure (CPAP) on blood pressure in patients with obstructive sleep apnea/hypopnea. A systemic review and meta-analysis. Chest Sep 26 2013, 10.1378/chest.13-1115.
39. Yang D., Liu Z., Yang H. The impact of effective continuous positive airway pressure on homeostasis model assessment insulin resistance in non-diabetic patients with moderate to severe obstructive sleep apnea. Diabetes Metab Res Rev 2012, 28(6):499-504.
40. Yang D., Liu Z., Yang H., et al. Effects of continuous positive airway pressure on glycemic control and insulin resistance in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2013, 17:33-38.
41. Polesel D.N., Nozoe K.T., Decleva D.V., et al. Obesity, dyslipidemia, and sleep disorders: complexity requires complementary analysis. Chest 2013, 143(4):1187-1188.
42. Malli F., Papaioannou A.I., Gourgoulianis K.I., et al. The role of leptin in the respiratory system: an overview. Respir Res 2010, 11:152.
43. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6(10):772-783.
44. Xie X., Pan L., Ren D., et al. Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-analysis. Sleep Med 2013, 14(11):1139-1150.
45. Katcher H.I., Hill A.M., Lanford J.L., et al. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am 2009, 38(1):45-78.
46. Karlawish J.H., Pack A.I. Addressing the ethical problems of randomized and placebo-controlled trials of CPAP. Am J Respir Crit Care Med 2001, 163(4):809-810.